HHC (hexahydrocannabinol) is a hydrogenated form of THC found in trace amounts in cannabis and produced synthetically from hemp-derived CBD. Whether HHC causes positive drug tests
HHC is produced by adding hydrogen atoms across the double bond of THC — a process called hydrogenation, similar to how margarine is produced from vegetable oil. This creates a more stable molecule with reduced oxidative degradation. HHC exists as two stereoisomers (9R-HHC and 9S-HHC) with 9R being more pharmacologically active, binding CB1 receptors with lower affinity than delta-9 THC. The metabolic pathway for HHC in humans is not fully characterised in peer-reviewed literature. Compare this to the well-studied delta-8 vs delta-9 metabolic pathways. Early evidence suggests HHC produces metabolites including 11-hydroxy-HHC that may cross-react with THC immunoassays.
Published analytical chemistry research has identified HHC metabolites in urine following HHC consumption. A 2023 case report in Clinical Chemistry described a forensic case where an HHC user tested positive on standard urine immunoassay. The cross-reactive metabolite appears to be 11-hydroxy-HHC, which shares structural similarities with 11-hydroxy-THC and may trigger antibodies in standard cannabis immunoassays. However, GC/MS confirmatory testing for THC-COOH may or may not confirm a positive depending on whether the assay specifically detects HHC-COOH analogues. The analytical picture is still emerging. The false positives guide explains why emerging cannabinoids create new cross-reactivity uncertainties.
Given the current evidence — documented cross-reactivity on immunoassay, uncertain GC/MS confirmation status, and inadequate human pharmacokinetic data — the conservative risk assessment is: assume HHC will trigger a positive on standard workplace drug tests. Anyone subject to federal, military, DOT, or security clearance testing should treat HHC identically to delta-9 THC from a risk standpoint. The argument that "HHC might not confirm on GC/MS" is legally and practically irrelevant because most workplaces treat a preliminary positive as grounds for adverse action pending confirmation. Compare to delta-8 THC drug test risk which has more established evidence of detectability.
Like delta-8, HHC is synthesised chemically from hemp-derived CBD. The synthesis process can produce by-products and may include residual delta-8 or delta-9 THC contamination. Independent testing of commercial HHC products has found variable cannabinoid profiles far from stated compositions. This means HHC products carry dual risk: their own potential cross-reactivity plus contamination with established THC-positive compounds. Military and federal employees are explicitly warned against all hemp-derived novel cannabinoids — see the military drug testing guide. Also review THCA drug test risks for the broader hemp-derived cannabinoid picture.